Celgene to Pay $280 Million to Settle Fraud Suit Over Cancer Drugs
The lawsuit accused the pharmaceutical company of marketing Thalomid and Revlimid for unapproved use on a broader range of cancers.
Source: NYT Health - Category: Consumer Health News Authors: KATIE THOMAS Tags: Drugs (Pharmaceuticals) Suits and Litigation (Civil) Thalidomide (Drug) Celgene Corporation Whistle-Blowers Cancer Food and Drug Administration Source Type: news
More News: Cancer | Cancer & Oncology | Food and Drug Administration (FDA) | Health | Lawsuits | Legislation | Marketing | Revlimid